Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Treasury Shares (2022 - 2025)

Taysha Gene Therapies' Treasury Shares history spans 4 years, with the latest figure at $6.3 million for Q3 2025.

  • For Q3 2025, Treasury Shares changed N/A year-over-year to $6.3 million; the TTM value through Sep 2025 reached $6.3 million, changed N/A, while the annual FY2024 figure was $4.5 million, 1112.97% up from the prior year.
  • Treasury Shares for Q3 2025 was $6.3 million at Taysha Gene Therapies, roughly flat from $6.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $6.3 million in Q2 2025 and bottomed at $69344.0 in Q1 2023.
  • The 4-year median for Treasury Shares is $1.3 million (2022), against an average of $2.4 million.
  • The largest annual shift saw Treasury Shares plummeted 75.04% in 2023 before it soared 1112.97% in 2024.
  • A 4-year view of Treasury Shares shows it stood at $1.3 million in 2022, then crashed by 70.18% to $375044.0 in 2023, then skyrocketed by 1112.97% to $4.5 million in 2024, then soared by 37.85% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Treasury Shares are $6.3 million (Q3 2025), $6.3 million (Q2 2025), and $6.2 million (Q1 2025).